H.R. 1629 117th Congress
Fairness in Orphan Drug Exclusivity Act
Latest action, May 20, 2021: Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
How the House voted: On Passage
May 19, 2021 · Passed · 402–23 (it needed 1/2)
- Yea (402)
- Nay (23)
- Didn't vote (4)
- Letters: party (D, R, I)
By party
- Democrat
- Republican
- Independent
Every roll call on it (2)
Each dot is a roll call, in order: how much of the House voted yea. The ringed one decided it.
- Carried
- Failed
See the data
| Date | Question | Result | Yea–nay |
|---|---|---|---|
| May 19, 2021 | On Passage | Passed | 402–23 |
| May 11, 2021 | On Motion to Suspend the Rules and Pass | Failed | 250–168 |
2 cosponsors
Sponsored by Madeleine Dean (Democrat). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
1 D · 1 R
- Democrat
- Republican
- Independent
Referred to: Senate: Health, Education, Labor, and Pensions Committee; House: Budget Committee; House: Energy and Commerce Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
BIOMARIN PHARMACEUTICAL INC.
CHAMBER HILL STRATEGIES
7 reports
TRAVERE THERAPEUTICS
ALSTON & BIRD LLP
7 reports
6 reports
BRAEBURN PHARMACEUTICALS, INC.
STANTON PARK GROUP
5 reports
1 report
All 9 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | House |
|---|---|---|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | CHAMBER HILL STRATEGIES | 7 | $0 | Q4 2021 | Q3 2022 | yes |
| TRAVERE THERAPEUTICS | ALSTON & BIRD LLP | 7 | $0 | Q4 2021 | Q3 2022 | yes |
| GSK (FKA GLAXOSMITHKLINE INC.) | 6 | $7.1M | Q1 2021 | Q2 2022 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 6 | $42.9M | Q4 2021 | Q3 2022 | yes | |
| BRAEBURN PHARMACEUTICALS, INC. | STANTON PARK GROUP | 5 | $200K | Q1 2021 | Q1 2022 | yes |
| BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC | 4 | $390K | Q1 2021 | Q3 2021 | yes | |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 3 | $9.7M | Q4 2021 | Q2 2022 | yes | |
| NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) | 1 | $50K | Q3 2021 | Q3 2021 | yes | |
| NOVARTIS | 1 | $1.5M | Q4 2021 | Q4 2021 | yes |